Frontera Therapeutics Doses First Patient in Phase 1 Clinical Trial for Gene Therapy FT-001 for the Treatment of Leber Congenital Amaurosis-2
BEDFORD, Mass., and SHANGHAI, China, January 6, 2023 — Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, today announced that it has dosed the first patient in a Phase 1 clinical trial of its lead gene …